PDT Partners LLC Invests $627,000 in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

PDT Partners LLC acquired a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 79,169 shares of the company's stock, valued at approximately $627,000.

Several other large investors have also recently bought and sold shares of the company. Nantahala Capital Management LLC lifted its stake in shares of Amneal Pharmaceuticals by 37.3% during the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company's stock valued at $29,031,000 after acquiring an additional 995,586 shares during the period. Northern Trust Corp lifted its position in Amneal Pharmaceuticals by 9.7% during the 4th quarter. Northern Trust Corp now owns 1,777,283 shares of the company's stock valued at $14,076,000 after purchasing an additional 156,699 shares during the period. Aquatic Capital Management LLC bought a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at about $456,000. Oxford Asset Management LLP acquired a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $440,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $368,000. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on AMRX shares. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Barclays lifted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals has an average rating of "Buy" and an average price target of $10.80.

Amneal Pharmaceuticals Stock Down 5.4 %

Shares of AMRX traded down $0.43 during trading hours on Monday, reaching $7.54. The stock had a trading volume of 2,733,660 shares, compared to its average volume of 1,419,906. The firm has a 50-day moving average of $8.02 and a 200 day moving average of $8.16. The company has a market cap of $2.34 billion, a P/E ratio of -11.09 and a beta of 1.17. Amneal Pharmaceuticals, Inc. has a 52 week low of $6.29 and a 52 week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The business had revenue of $695.42 million during the quarter, compared to analyst estimates of $714.78 million. As a group, equities analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the transaction, the director now owns 1,808,886 shares of the company's stock, valued at approximately $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.